ASTRAZEN2024-07-012024-09-30 ASTRAZEN2024-07-012024-09-30 ASTRAZEN2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member ASTRAZEN2024-07-012024-09-30in-bse-fin:OneOperatingExpenses02Member ASTRAZEN2024-07-012024-09-30in-bse-fin:OneOperatingExpenses03Member ASTRAZEN2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member ASTRAZEN2024-07-012024-09-30in-bse-fin:FourOperatingExpenses02Member ASTRAZEN2024-07-012024-09-30in-bse-fin:FourOperatingExpenses03Member ASTRAZEN2024-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 506820 ASTRAZEN NA AstraZeneca Pharma India Limited Equity 2024-04-01 2025-03-31 2024-11-13 2024-10-26 INR Millions Half yearly 10:00:00 16:10:00 2024-11-13 2024-11-13 true Cash Flow Indirect Not applicable Single segment Healthcare 2024-07-01 2024-09-30 Unaudited Standalone 4079960000.00 81540000.00 4161500000.00 771450000.00 2518740000.00 -1030890000.00 680440000.00 3440000.00 93150000.00 614840000.00 3651170000.00 510330000.00 0.00 510330000.00 146990000.00 -20960000.00 126030000.00 0.00 384300000.00 0.00 0.00 0.00 0.00 384300000.00 -16530000.00 367770000.00 0.00 0.00 50000000.00 2 15.37 15.37 0.00 0.00 15.37 15.37 Notes: 1.The Statements of unaudited financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India. 2. The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided. 3. Exceptional items a). In continuation with the Company’s earlier announcement of intent to exit its manufacturing site on 16 November 2023, the Company explored the option of sale of the manufacturing site in a fully operational manner to a Contract Manufacturing Organisation. The Company was unable to find a suitable one and has made an announcement to Stock exchanges on 21 June 2024 that it will now explore a buyer for its manufacturing site and exit in due course. The exit is estimated to take more than 12 months. Consequently, the company has accounted for provisions related to closure of its manufacturing site amounting to Rs.575.6 Million as exceptional item for the quarter ended 30 June 2024 and half-year ended 30 September 2024 as per the relevant Indian Accounting Standards. b). The Company had entered into an Advance Pricing Agreement with Central Board of Direct Taxation for financial years 2015-2016 to 2019-2020 for which there were certain previously disclosed disputed Transfer Pricing matters consequent to which an amount of Rs.164.3 Million is disclosed as an exceptional income for the half-year ended 30 September 2023 and year ended 31 March 2024. 4. This Statement of unaudited financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 13 November 2024. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter and half-year ended 30 September 2024. 5. The Company has decided to change the rounding off principle followed in the Statement of financial results from lakhs of rupees to millions of rupees from the previous quarter. By Order of the Board of Directors For AstraZeneca Pharma India Limited Place: Bengaluru Sanjeev Kumar Panchal Date: 13 November 2024 Managing Director Single segment 2024-04-01 2024-09-30 Unaudited Standalone 7955180000.00 165030000.00 8120210000.00 1229960000.00 4922030000.00 -1588320000.00 1290000000.00 4520000.00 132260000.00 1195420000.00 7185870000.00 934340000.00 -575630000.00 358710000.00 254530000.00 -162190000.00 92340000.00 0.00 266370000.00 0.00 0.00 0.00 0.00 266370000.00 -9110000.00 257260000.00 0.00 0.00 50000000.00 2 10.65 10.65 0.00 0.00 10.65 10.65 Allowance for expected credit loss (net) 27880000.00 Other Expenses 369550000.00 Selling, marketing and distribution expenses 217410000.00 Allowance for expected credit loss (net) 17680000.00 Other Expenses 776640000.00 Selling, marketing and distribution expenses 401100000.00 672500000.00 2050000.00 0.00 0.00 19010000.00 0.00 0.00 0.00 0.00 0.00 2370000.00 51040000.00 53410000.00 377810000.00 622920000.00 1747700000.00 3819880000.00 0.00 1497560000.00 4965240000.00 2640000.00 3290000.00 111950000.00 6580680000.00 0.00 264800000.00 10665360000.00 0.00 0.00 12413060000.00 50000000.00 6743550000.00 6793550000.00 6793550000.00 0.00 0.00 133310000.00 133310000.00 632940000.00 0.00 0.00 105000000.00 871250000.00 0.00 3169120000.00 428810000.00 3597930000.00 680030000.00 444670000.00 25630000.00 0.00 4748260000.00 0.00 0.00 5619510000.00 12413060000.00 4520000.00 -1541060000.00 16030000.00 0.00 13720000.00 0.00 -25990000.00 65660000.00 0.00 1212700000.00 0.00 -97140000.00 105000000.00 132260000.00 0.00 0.00 -1800000.00 74560000.00 0.00 -9050000.00 0.00 163480000.00 26690000.00 0.00 0.00 -740000.00 0.00 588510000.00 0.00 400390000.00 759100000.00 0.00 0.00 0.00 374630000.00 0.00 384470000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1220000.00 6960000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 162790000.00 0.00 0.00 0.00 157050000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 31980000.00 0.00 600000000.00 0.00 0.00 0.00 -631980000.00 -90460000.00 0.00 -90460000.00 5055690000.00 4965230000.00 -22080000.00 -12200000.00 -5550000.00 -3090000.00 0.00 0.00